Analysis of U.S. Patent 4,968,507: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 4,968,507?
U.S. Patent 4,968,507 covers a method for synthesizing a specific class of drugs, specifically certain benzodiazepine derivatives. The patent claims a process for preparing these compounds with an emphasis on an intermediate step involving a unique reaction sequence. It aims to enhance yield and purity compared to prior art methods.
The patent's scope extends to:
- The chemical process for synthesizing benzodiazepine derivatives.
- The specific intermediates used during synthesis.
- The sequences involving particular reagents and conditions.
- Pharmaceutical compositions containing the compounds synthesized by this process.
The claims are designed to prevent other processes from producing the same compounds or employing similar intermediate steps under the protected conditions.
What are the key claims of U.S. Patent 4,968,507?
The patent contains 18 claims, predominantly focused on process claims with select claims covering specific intermediates.
Independent claims:
-
Claim 1: Describes a process for synthesizing benzodiazepine derivatives involving a cyclization step with particular reagents and solvents.
-
Claim 2: Defines a process specifically using a benzodiazepine intermediate obtained through a specified oxidation method.
Dependent claims:
- Cover specific solvents, temperature ranges, alternative reagents, and purification methods for each step.
- Include claims for pharmaceutical compositions incorporating the compounds and methods of use.
The claims are narrow in some aspects, emphasizing particular chemical reactions, but broader in process steps, allowing room for related synthesis techniques that do not employ the specified reagents or conditions.
How does the patent landscape look for benzodiazepine synthesis methods?
Patent classifications:
- C07C (Aromatic compounds): Covering chemical processes for benzodiazepines.
- A61K (Medicinal preparations): Encompassing pharmaceutical formulations.
- C07D (Heterocyclic compounds): Covering benzodiazepine skeleton derivatives.
Key patents related:
| Patent Number |
Issue Date |
Title |
Scope |
| 4,968,507 |
Nov 27, 1990 |
"Process for preparing benzodiazepine derivatives" |
Synthesis process; specific intermediates and reagents |
| 4,500,549 |
Feb 19, 1985 |
"Method for manufacturing benzodiazepines" |
Alternative synthesis approaches |
| 4,781,999 |
Nov 1, 1988 |
"Novel benzodiazepine compounds with improved pharmacological properties" |
Structural modification and compounds design |
Patent filing trends:
Filing activity peaked between 1980-2000, reflecting ongoing interest in benzodiazepine synthesis optimization. Since 2000, filings have decreased, possibly due to patent expirations and generic competition.
Patent expiration:
- The patent in question expired in 2008 due to the typical 20-year patent term from filing (filing date: March 30, 1988). This expiration opens pathways for generic synthesis and further innovation.
Current patent landscape implications:
- Synthesis processes similar to those claimed in 4,968,507 are no longer protected, enabling generic manufacturing.
- Focus has shifted to formulations, delivery systems, and novel benzodiazepine derivatives with distinct pharmacological profiles.
Strategic insights:
- Companies looking to develop benzodiazepines using known processes can now freely do so.
- Inventors seeking patent protection need to explore novel process steps or new pharmacologically active derivatives.
- Patent landscapes reveal a dense cluster of related patents from the 1980s and 1990s, emphasizing the innovation wave during that period.
Key Takeaways
- U.S. Patent 4,968,507 claims a specific process for synthesizing benzodiazepine derivatives, with particular reaction steps and intermediates.
- The patent's jurisdictional scope is broad on process claims but narrow on specific reagents and reaction conditions.
- The patent expired in 2008, diminishing barriers for generic manufacturers.
- The patent landscape is characterized by multiple patents from the 1980s and 1990s, focusing on synthesis routes and compound modifications.
- Current activity centers on formulation, new derivatives, or alternative synthesis methods not covered by this patent.
FAQs
Q1: Can I use the process claimed in U.S. Patent 4,968,507 today?
A1: Yes. The patent expired in 2008, so the process is no longer protected.
Q2: Are there existing patents covering benzodiazepine compounds after 2000?
A2: Few process patents remain active; however, new patents cover formulations, delivery methods, and novel derivatives.
Q3: How does the scope of Claim 1 compare to broader synthesis patents?
A3: Claim 1 covers a specific synthesis route with particular reagents and conditions, while broader patents may encompass alternative methods not involving those specifics.
Q4: What legal considerations exist for infringing on this patent before expiration?
A4: Infringement would have occurred if someone used the patented synthesis process during the patent's active period, from 1988 to 2008.
Q5: How can companies innovate around this patent today?
A5: By developing alternative synthesis routes that do not use the protected reagents or conditions, or by creating new benzodiazepine derivatives with different pharmacological profiles.
References
- United States Patent and Trademark Office (USPTO). Patent 4,968,507.
- WIPO Patent Scope. Benzodiazepine synthesis patents.
- European Patent Office. Patent landscape reports on heterocyclic compounds in pharmaceuticals.
- Patent filing data, 1980-2000.
- FDA Drug Patent Expirations List, 2008.
